Relugolix

QYResearch调研显示，2025年全球前列腺肿瘤药品市场销售额达到了157.8亿美元，预计2032年市场规模将为332.1亿美元，2026—2032期间年复合增长率（CAGR）为11.2%。该产品的平均毛利率是75%，高毛利水平充分印证了前列腺肿瘤药品赛道的技术壁垒与价值密度，使其成为全球肿瘤药物市场中最具吸引力的细分领域之一。 编辑 搜图 前列腺肿瘤药品（Prostate Tumor Drugs）是指用于预防、控制和治疗前列腺癌及相关恶性肿瘤的一类医药产品。该类药物主要通过抑制雄激素信号通路、阻断肿瘤细胞增殖或诱导癌细胞凋亡来发挥治疗作用，涵盖雄激素剥夺治疗药物（ADT）、雄激素受体拮抗剂、雄激素合成抑制剂、化疗药物以及新兴的靶向治疗和放射性配体疗法等多种类别。前列腺癌的发病与雄激素水平密切相关，因此控制体内雄激素的生成和受体活性是临床治疗的核心策略。随着分子靶向药物和免疫疗法的发展，部分前列腺肿瘤药品已能够针对特定基因突变或蛋白表达异常进行精准治疗，从而提高疗效并降低副作用。按产品类型，市场分为雄激素受体抑制剂、PARP抑制剂、放射性配体治疗、激素治疗及其他五大类别；按应用主要包括医院、零售药房及其他渠道，其中医院渠道占据最大市场份额，约为70%。 从供应链结构看，上游主要包括活性药物成分（API）、制剂辅料以及生产工艺设备等环节。API通常涵盖小分子化学药物、生物大分子及蛋白质类抑制剂，需通过高纯度合成或生物工程方法制备，并严格保证稳定性和活性。制剂辅料包括缓释材料、包衣、稳定剂等，用于改善药物口服吸收或控制药效释放。生产工艺设备涉及反应釜、纯化系统和无菌制备设施等，对环境控制、质量管理和工艺稳定性要求极高。下游需求主要来自医院、癌症专科医疗机构、药品经销渠道及患者自购渠道。随着诊断技术提升和早期筛查普及，患者群体逐渐扩大，对高效、低副作用药物的需求显著增长。 第一、主要生产商企业画像：国际巨头主导高端，中国力量加速突围 全球前列腺肿瘤药品市场集中度较高，由少数国际制药巨头主导。Bayer（拜耳）是全球肿瘤药物领域的领军企业，其核药业务线Nubeqa（达罗他胺）是新一代雄激素受体抑制剂，2024年全球销售额突破25亿欧元，在前列腺癌治疗领域表现突出。Astellas（安斯泰来）总部位于日本东京，其Xtandi（恩扎卢胺）是全球最畅销的前列腺癌口服药物之一，2024年销售额超50亿美元。Pfizer（辉瑞）总部位于美国纽约，其Xtandi与Talzenna（他拉唑帕利）在PARP抑制剂领域占据重要地位。Johnson & Johnson（强生）旗下Zytiga（阿比特龙）曾是前列腺癌治疗的标杆药物，其核药Pluvicto更是首个获批的放射性配体疗法，开创了治疗新范式。Sanofi（赛诺菲）与Novartis（诺华）在肿瘤管线布局深厚，AstraZeneca（阿斯利康）的Lynparza（奥拉帕利）在BRCA突变前列腺癌中表现优异。AbbVie（艾伯维）的Orgovyx（瑞卢戈利）是首个口服GnRH受体拮抗剂，Takeda（武田制药）在亚洲市场肿瘤业务增长迅速。Amgen（安进）、Ferring（费林）及Ipsen（易普森）在特定细分领域各有建树。 中国企业方面，恒瑞医药是国内抗肿瘤药物龙头，其阿帕他胺是首个国产雄激素受体抑制剂，已纳入医保目录，2024年肿瘤板块营收突破120亿元。恒瑞医药在前列腺癌管线中布局了多款创新药，包括PARP抑制剂及下一代AR靶向药物，研发投入持续加码。整体来看，中国企业凭借成本优势与快速研发迭代，在中端市场及部分高端领域逐步提升竞争力，但在放射性配体疗法等前沿技术领域仍与国际巨头存在差距。 第二、政策与贸易变局：关税加码倒逼全球化战略升级 在美国关税政策持续加码的背景下，中国前列腺肿瘤药品企业面临出口成本激增、供应链重构与市场准入受限等多重挑战。受中美贸易摩擦持续升级影响，中国生物医药企业出口至北美的制剂产品面临高额关税壁垒，直接推高出口成本，尤其对外销比重较高的企业，不确定性和风险持续增加。这一政策环境倒逼中国企业加速重构全球供应链布局，并通过市场多元化、技术突围与合规升级寻求战略破局。 为应对挑战，中国企业需采取多维度策略。供应链层面，通过"区域制造中心+本地化生产"模式优化布局。市场拓展层面，加速开拓东南亚、中东、拉美等新兴市场，并结合本地需求开发差异化产品。品牌与技术层面，推动从"低价竞争"向高附加值转型。展望未来，国际贸易规则重构与数字贸易兴起为中国企业提供新机遇。中国企业需建立动态风险管理机制，并依托"一带一路"深化区域协同（金砖国家产能合作），方能从"成本依赖型出口"转向"技术—品牌双驱动"的全球化新范式。 第三、发展趋势：三重引擎驱动，精准医疗与核药引领行业变革 从行业前景看，市场驱动因素主要有三：其一，全球人口老龄化加速与男性健康意识提升。前列腺癌是全球男性第二大常见癌症，2025年全球新增病例预计超150万例，早期筛查和诊断的不断普及为市场提供了持续增长的需求基础。其二，精准医疗与个性化治疗理念的深入推进。先进的分子生物学和药物研发技术使得针对雄激素受体、基因突变和特定信号通路的靶向药物不断涌现，国际临床指南已将新型雄激素抑制剂和放射性配体疗法纳入标准治疗方案，为市场提供制度性支持。其三，PARP抑制剂与放射性配体疗法等新兴品类快速放量。以Pluvicto为代表的核药疗法2024年全球销售额突破10亿美元，增速超过80%，成为行业最大增量来源。 展望未来，前列腺肿瘤药品行业将呈现三大趋势：首先，放射性配体疗法（RLT）将成为重要增长极。以Lu-177为代表的靶向核药正在重塑晚期前列腺癌治疗格局，市场规模有望在2030年前突破50亿美元。其次，PARP抑制剂与免疫疗法的联合用药方案将加速临床转化，推动精准治疗向多机制协同方向演进。最后，数字医疗与伴随诊断技术的融合，将推动药物与检测一体化解决方案的普及，提升患者用药精准度。 按地区分析，北美市场是全球最大的消费市场，占比约为45%，受FDA加速审批政策及高支付能力支撑，创新药物渗透率最高。欧洲市场以德国、法国、英国为核心，医保覆盖体系完善，PARP抑制剂及核药疗法增长迅速。亚太市场增速最快，中国与印度是核心增长引擎，受医保扩容与国产替代推动，市场份额持续提升。南美及中东非洲市场受益于"一带一路"医疗合作项目，需求逐步释放。 第四、行业前景与投资建议：从"仿制跟随"走向"创新引领" 从市场分析角度看，11.2%的年复合增长率叠加75%的高毛利率，使前列腺肿瘤药品赛道具备"高壁垒、高增长、高回报"三重属性，成为中长期配置的优质标的。行业面临的挑战亦不容忽视：前列腺癌存在显著个体差异性，不同患者对药物的敏感性和耐受性差异较大，使得药物研发和临床推广难度加大；高端靶向药物和新型治疗方案价格昂贵，限制了部分市场的普及和患者可及性；临床试验周期长、监管审批严格，也可能延缓新药上市速度并增加企业研发风险。 对于专业投资者而言，建议重点关注以下方向：一是具备核药与PARP抑制剂研发管线的创新药企，如恒瑞医药，其多款前列腺癌创新药已进入临床后期；二是已进入国际肿瘤药物供应链的中国企业，有望借助"一带一路"拓展新兴市场；三是在放射性配体疗法等前沿技术领域率先卡位的细分冠军。同时，需密切关注FDA及EMA审批动态、各国医保政策变化及全球老龄化趋势，这些因素将直接影响前列腺肿瘤药品的市场景气度与投资回报。 《2026-2032全球与中国前列腺肿瘤药品市场现状及未来发展趋势》报告中，QYResearch研究全球与中国市场 前列腺肿瘤药品的产能、产量、销量、销售额、价格、总体规模、上下游、驱动因素、发展机遇、未来趋势及全球和中国市场主要生产商的市场份额等等。历史数据为2021至2025年，预测数据为2026至2032年。篇幅较长，请查看完整报告。

SMPA reinforces commitment to the urology community with findings from studies across overactive bladder and advanced prostate cancer portfolios MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May 15–18 in Washington, D.C. The presentations include a featured subgroup analysis of the phase 3 COURAGE trial evaluating vibegron in older men, along with real-world evidence from the OPTYX study of relugolix in advanced prostate cancer. “Our presence at AUA 2026 underscores our deep-rooted commitment to advancing scientific understanding for patients managing complex urologic conditions,” said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. “By focusing on patient populations at particular risk, such as men over 75 with overactive bladder and on pharmacologic treatment for benign prostatic hyperplasia, and those navigating the complexities of advanced prostate cancer, we aim to provide clinicians with the robust data they need to make informed, patient-centered treatment decisions.” Safety and efficacy outcomes with vibegron are comparable in older and younger patients Data presented includes a poster on a subgroup analysis of the placebo-controlled phase 3 COURAGE trial, which evaluated the efficacy and safety of once-daily vibegron 75 mg in men with symptoms of overactive bladder (OAB) who were also receiving pharmacologic therapy for benign prostatic hyperplasia (BPH) (stable dose of α-blocker ± 5α-reductase inhibitors). The analysis found that men ≥75 years experienced clinically meaningful reductions from baseline at week 24 in average daily number of micturitions and urgency episodes with vibegron (n=92) compared with placebo (n=100). Micturitions were –2.3 in the vibegron group compared with –1.5 in the placebo group, and urgency episodes were –3.6 in the vibegron group compared with –2.3 in the placebo group. These results were comparable to the outcomes observed in men <75 years. Vibegron was generally well tolerated in this older population, with a safety pro to that observed in men <75 years. “Older men often face the dual challenge of managing OAB symptoms while on existing therapies for BPH. These findings are encouraging as they demonstrate that vibegron can provide meaningful symptomatic relief in this specific, often harder-to-treat population, with a safety pro to that of younger patients,” said Dr. Sender Herschorn, M.D., Professor of Surgery/Urology at the University of Toronto and lead author of the poster. Additional data presented in treatment of OAB and advanced prostate cancer In a separate podium presentation, SMPA shared a subgroup analysis from the COURAGE trial evaluating the effect of vibegron on sexual function in men. SMPA, in a poster presentation, also shared an interim analysis of testosterone suppression and recovery from the OPTYX study, a prospective, long-term observational study of relugolix (monotherapy and combination) in a real-world setting. Presentation Details Title Details IP15-20: Efficacy and safety of vibegron in men ≥75 years of age with symptoms of overactive bladder on pharmacotherapy for benign prostatic hyperplasia: a subgroup analysis of the COURAGE trial Poster Presentation Presenter: Dr. Sender Herschorn, MD, University of Toronto IP38-21: Testosterone suppression and recovery in patients with advanced prostate cancer treated with relugolix: an interim analysis of the OPTYX study Poster Presentation​ Presenter: Dr. Benjamin Lowenritt, MD, FACS, Chesapeake Urology PD26-08: Evaluating sexual function in men treated with vibegron for overactive bladder while on pharmacological therapy for benign prostatic hyperplasia: exploratory analysis from the phase 3 COURAGE trial​ Podium Presentation​ Presenter: Dr. Kenneth Peters, MD, Urology, Corewell Health William Beaumont University Hospital About GEMTESA ® (vibegron) In the U.S., GEMTESA (vibegron) has been indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults since December 2020. GEMTESA was approved in December 2024, for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). GEMTESA works by selectively targeting beta-3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity. About Overactive Bladder Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), and frequent urination (usually eight or more times in 24 hours). 1 Approximately 33 million U.S. adults experience the bothersome symptoms of OAB. 2 INDICATIONS AND USAGE GEMTESA ® is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred. WARNINGS AND PRECAUTIONS Urinary Retention Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention. Angioedema Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway. ADVERSE REACTIONS Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection. Please see full Prescribing Information . ABOUT ORGOVYX ® (relugolix) ORGOVYX ® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer. IMPORTANT SAFETY INFORMATION Contraindication ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components. Warnings and Precautions QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated. Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX. Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured. Adverse Reactions Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX. Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%). Drug Interactions Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a 360 mg loading dose on the first day and continue with 120 mg once daily. Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily. Please see full Prescribing Information for ORGOVYX. About Sumitomo Pharma Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With products in the U.S., Canada, and Europe, and a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website or follow us on LinkedIn . The Sumitomo corporate symbol mark is a registered trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. GEMTESA and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. ORGOVYX ® and its logo are registered trademarks of Sumitomo Pharma Co. Ltd., used under license. ©2026 Sumitomo Pharma America, Inc. All rights reserved. References Overactive bladder – symptoms and causes. Mayo Clinic. February 4, 2025. Accessed May 6, 2026. Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol. 2011;3:7-17. doi:10.2147/OAJU.S7233 GEMTESA. Prescribing Information. Marlborough, MA; Sumitomo Pharma America; 2025 Contacts For further information: SMPA CONTACT: Dave Murdoch, Sumitomo Pharma America, Inc., david.murdoch@us.sumitomo-pharma.com , +1 (774) 405-5570